#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Expectation effects on brain dopamine responses to methylphenidate in cocaine use disorder The response to drugs of abuse is affected by expectation, which is modulated in part by dopamine (DA), which encodes for a reward prediction error.
1-1	0-11	Expectation	_
1-2	12-19	effects	_
1-3	20-22	on	_
1-4	23-28	brain	_
1-5	29-37	dopamine	_
1-6	38-47	responses	_
1-7	48-50	to	_
1-8	51-66	methylphenidate	_
1-9	67-69	in	_
1-10	70-77	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-11	78-81	use	_
1-12	82-90	disorder	_
1-13	91-94	The	_
1-14	95-103	response	_
1-15	104-106	to	_
1-16	107-112	drugs	_
1-17	113-115	of	_
1-18	116-121	abuse	_
1-19	122-124	is	_
1-20	125-133	affected	_
1-21	134-136	by	_
1-22	137-148	expectation	_
1-23	149-150	,	_
1-24	151-156	which	_
1-25	157-159	is	_
1-26	160-169	modulated	_
1-27	170-172	in	_
1-28	173-177	part	_
1-29	178-180	by	_
1-30	181-189	dopamine	_
1-31	190-191	(	_
1-32	192-194	DA	_
1-33	195-196	)	_
1-34	197-198	,	_
1-35	199-204	which	_
1-36	205-212	encodes	_
1-37	213-216	for	_
1-38	217-218	a	_
1-39	219-225	reward	_
1-40	226-236	prediction	_
1-41	237-242	error	_
1-42	243-244	.	_

Text=Here we assessed the effect of expectation on methylphenidate (MP) -induced striatal DA changes in 23 participants with an active cocaine use disorder (CUD) and 23 healthy controls (HC) using [11C] raclopride and PET both after placebo (PL) and after MP (0.5 mg/kg, i.v .).
2-1	245-249	Here	_
2-2	250-252	we	_
2-3	253-261	assessed	_
2-4	262-265	the	_
2-5	266-272	effect	_
2-6	273-275	of	_
2-7	276-287	expectation	_
2-8	288-290	on	_
2-9	291-306	methylphenidate	_
2-10	307-308	(	_
2-11	309-311	MP	_
2-12	312-313	)	_
2-13	314-322	-induced	_
2-14	323-331	striatal	_
2-15	332-334	DA	_
2-16	335-342	changes	_
2-17	343-345	in	_
2-18	346-348	23	_
2-19	349-361	participants	_
2-20	362-366	with	_
2-21	367-369	an	_
2-22	370-376	active	http://maven.renci.org/NeuroBridge/neurobridge#Activity
2-23	377-384	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
2-24	385-388	use	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
2-25	389-397	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
2-26	398-399	(	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
2-27	400-403	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
2-28	404-405	)	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveDisorder
2-29	406-409	and	_
2-30	410-412	23	_
2-31	413-420	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-32	421-429	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-33	430-431	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-34	432-434	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-35	435-436	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
2-36	437-442	using	_
2-37	443-444	[	_
2-38	445-448	11C	_
2-39	449-450	]	_
2-40	451-461	raclopride	_
2-41	462-465	and	_
2-42	466-469	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
2-43	470-474	both	_
2-44	475-480	after	_
2-45	481-488	placebo	_
2-46	489-490	(	_
2-47	491-493	PL	_
2-48	494-495	)	_
2-49	496-499	and	_
2-50	500-505	after	_
2-51	506-508	MP	_
2-52	509-510	(	_
2-53	511-514	0.5	_
2-54	515-520	mg/kg	_
2-55	521-522	,	_
2-56	523-526	i.v	_
2-57	527-528	.	_
2-58	529-530	)	_
2-59	531-532	.	_

Text=Brain dopamine D2 and D3 receptor availability (D2R: non-displaceable binding potential (BPND)) was measured under four conditions in randomized order: (1) expecting PL/receiving PL, (2) expecting PL/receiving MP, (3) expecting MP/receiving PL, and (4) expecting MP/receiving MP.
3-1	533-538	Brain	_
3-2	539-547	dopamine	_
3-3	548-550	D2	_
3-4	551-554	and	_
3-5	555-557	D3	_
3-6	558-566	receptor	_
3-7	567-579	availability	_
3-8	580-581	(	_
3-9	582-585	D2R	_
3-10	586-587	:	_
3-11	588-604	non-displaceable	_
3-12	605-612	binding	_
3-13	613-622	potential	_
3-14	623-624	(	_
3-15	625-629	BPND	_
3-16	630-631	)	_
3-17	632-633	)	_
3-18	634-637	was	_
3-19	638-646	measured	_
3-20	647-652	under	_
3-21	653-657	four	_
3-22	658-668	conditions	_
3-23	669-671	in	_
3-24	672-682	randomized	_
3-25	683-688	order	_
3-26	689-690	:	_
3-27	691-692	(	_
3-28	693-694	1	_
3-29	695-696	)	_
3-30	697-706	expecting	_
3-31	707-719	PL/receiving	_
3-32	720-722	PL	_
3-33	723-724	,	_
3-34	725-726	(	_
3-35	727-728	2	_
3-36	729-730	)	_
3-37	731-740	expecting	_
3-38	741-753	PL/receiving	_
3-39	754-756	MP	_
3-40	757-758	,	_
3-41	759-760	(	_
3-42	761-762	3	_
3-43	763-764	)	_
3-44	765-774	expecting	_
3-45	775-787	MP/receiving	_
3-46	788-790	PL	_
3-47	791-792	,	_
3-48	793-796	and	_
3-49	797-798	(	_
3-50	799-800	4	_
3-51	801-802	)	_
3-52	803-812	expecting	_
3-53	813-825	MP/receiving	_
3-54	826-828	MP	_
3-55	829-830	.	_

Text=Expecting MP increased pulse rate compared to expecting PL.
4-1	831-840	Expecting	_
4-2	841-843	MP	_
4-3	844-853	increased	_
4-4	854-859	pulse	_
4-5	860-864	rate	_
4-6	865-873	compared	_
4-7	874-876	to	_
4-8	877-886	expecting	_
4-9	887-889	PL	_
4-10	890-891	.	_

Text=Receiving MP decreased D2R in striatum compared to PL, indicating MP-induced striatal DA release, and this effect was significantly blunted in CUD versus HC consistent with prior findings of decreased striatal dopamine responses both in active and detoxified CUD.
5-1	892-901	Receiving	_
5-2	902-904	MP	_
5-3	905-914	decreased	_
5-4	915-918	D2R	_
5-5	919-921	in	_
5-6	922-930	striatum	_
5-7	931-939	compared	_
5-8	940-942	to	_
5-9	943-945	PL	_
5-10	946-947	,	_
5-11	948-958	indicating	_
5-12	959-969	MP-induced	_
5-13	970-978	striatal	_
5-14	979-981	DA	_
5-15	982-989	release	_
5-16	990-991	,	_
5-17	992-995	and	_
5-18	996-1000	this	_
5-19	1001-1007	effect	_
5-20	1008-1011	was	_
5-21	1012-1025	significantly	_
5-22	1026-1033	blunted	_
5-23	1034-1036	in	_
5-24	1037-1040	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
5-25	1041-1047	versus	_
5-26	1048-1050	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-27	1051-1061	consistent	_
5-28	1062-1066	with	_
5-29	1067-1072	prior	_
5-30	1073-1081	findings	_
5-31	1082-1084	of	_
5-32	1085-1094	decreased	_
5-33	1095-1103	striatal	_
5-34	1104-1112	dopamine	_
5-35	1113-1122	responses	_
5-36	1123-1127	both	_
5-37	1128-1130	in	_
5-38	1131-1137	active	_
5-39	1138-1141	and	_
5-40	1142-1152	detoxified	_
5-41	1153-1156	CUD	_
5-42	1157-1158	.	_

Text=There was a group × challenge × expectation effect in caudate and midbrain, with expectation of MP increasing MP-induced DA release in HC but not in CUD, and expectation of PL showing a trend to increase MP-induced DA release in CUD but not in HC.
6-1	1159-1164	There	_
6-2	1165-1168	was	_
6-3	1169-1170	a	_
6-4	1171-1176	group	_
6-5	1177-1178	×	_
6-6	1179-1188	challenge	_
6-7	1189-1190	×	_
6-8	1191-1202	expectation	_
6-9	1203-1209	effect	_
6-10	1210-1212	in	_
6-11	1213-1220	caudate	_
6-12	1221-1224	and	_
6-13	1225-1233	midbrain	_
6-14	1234-1235	,	_
6-15	1236-1240	with	_
6-16	1241-1252	expectation	_
6-17	1253-1255	of	_
6-18	1256-1258	MP	_
6-19	1259-1269	increasing	_
6-20	1270-1280	MP-induced	_
6-21	1281-1283	DA	_
6-22	1284-1291	release	_
6-23	1292-1294	in	_
6-24	1295-1297	HC	_
6-25	1298-1301	but	_
6-26	1302-1305	not	_
6-27	1306-1308	in	_
6-28	1309-1312	CUD	_
6-29	1313-1314	,	_
6-30	1315-1318	and	_
6-31	1319-1330	expectation	_
6-32	1331-1333	of	_
6-33	1334-1336	PL	_
6-34	1337-1344	showing	_
6-35	1345-1346	a	_
6-36	1347-1352	trend	_
6-37	1353-1355	to	_
6-38	1356-1364	increase	_
6-39	1365-1375	MP-induced	_
6-40	1376-1378	DA	_
6-41	1379-1386	release	_
6-42	1387-1389	in	_
6-43	1390-1393	CUD	_
6-44	1394-1397	but	_
6-45	1398-1401	not	_
6-46	1402-1404	in	_
6-47	1405-1407	HC	_
6-48	1408-1409	.	_

Text=These results are consistent with the role of DA in reward prediction error in the human brain: decreasing DA signaling when rewards are less than expected (blunted DA increases to MP in CUD) and increasing them when greater than expected (for PL in CUD reflecting conditioned responses to injection).
7-1	1410-1415	These	_
7-2	1416-1423	results	_
7-3	1424-1427	are	_
7-4	1428-1438	consistent	_
7-5	1439-1443	with	_
7-6	1444-1447	the	_
7-7	1448-1452	role	_
7-8	1453-1455	of	_
7-9	1456-1458	DA	_
7-10	1459-1461	in	_
7-11	1462-1468	reward	_
7-12	1469-1479	prediction	_
7-13	1480-1485	error	_
7-14	1486-1488	in	_
7-15	1489-1492	the	_
7-16	1493-1498	human	_
7-17	1499-1504	brain	_
7-18	1505-1506	:	_
7-19	1507-1517	decreasing	_
7-20	1518-1520	DA	_
7-21	1521-1530	signaling	_
7-22	1531-1535	when	_
7-23	1536-1543	rewards	_
7-24	1544-1547	are	_
7-25	1548-1552	less	_
7-26	1553-1557	than	_
7-27	1558-1566	expected	_
7-28	1567-1568	(	_
7-29	1569-1576	blunted	_
7-30	1577-1579	DA	_
7-31	1580-1589	increases	_
7-32	1590-1592	to	_
7-33	1593-1595	MP	_
7-34	1596-1598	in	_
7-35	1599-1602	CUD	_
7-36	1603-1604	)	_
7-37	1605-1608	and	_
7-38	1609-1619	increasing	_
7-39	1620-1624	them	_
7-40	1625-1629	when	_
7-41	1630-1637	greater	_
7-42	1638-1642	than	_
7-43	1643-1651	expected	_
7-44	1652-1653	(	_
7-45	1654-1657	for	_
7-46	1658-1660	PL	_
7-47	1661-1663	in	_
7-48	1664-1667	CUD	_
7-49	1668-1678	reflecting	_
7-50	1679-1690	conditioned	_
7-51	1691-1700	responses	_
7-52	1701-1703	to	_
7-53	1704-1713	injection	_
7-54	1714-1715	)	_
7-55	1716-1717	.	_

Text=Our findings also document disruption of the expectation of drug effects in dopamine signaling in participants with CUD compared to non-addicted individuals.
8-1	1718-1721	Our	_
8-2	1722-1730	findings	_
8-3	1731-1735	also	_
8-4	1736-1744	document	_
8-5	1745-1755	disruption	_
8-6	1756-1758	of	_
8-7	1759-1762	the	_
8-8	1763-1774	expectation	_
8-9	1775-1777	of	_
8-10	1778-1782	drug	_
8-11	1783-1790	effects	_
8-12	1791-1793	in	_
8-13	1794-1802	dopamine	_
8-14	1803-1812	signaling	_
8-15	1813-1815	in	_
8-16	1816-1828	participants	_
8-17	1829-1833	with	_
8-18	1834-1837	CUD	_
8-19	1838-1846	compared	_
8-20	1847-1849	to	_
8-21	1850-1862	non-addicted	_
8-22	1863-1874	individuals	_
8-23	1875-1876	.	_

Text=Methods Subjects The Institutional Review Boards at the Stony Brook University/Brookhaven National Laboratory approved the protocol.
9-1	1877-1884	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
9-2	1885-1893	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
9-3	1894-1897	The	_
9-4	1898-1911	Institutional	_
9-5	1912-1918	Review	_
9-6	1919-1925	Boards	_
9-7	1926-1928	at	_
9-8	1929-1932	the	_
9-9	1933-1938	Stony	_
9-10	1939-1944	Brook	_
9-11	1945-1966	University/Brookhaven	_
9-12	1967-1975	National	_
9-13	1976-1986	Laboratory	_
9-14	1987-1995	approved	_
9-15	1996-1999	the	_
9-16	2000-2008	protocol	_
9-17	2009-2010	.	_

Text=Written informed consent was obtained after the experimental procedure was explained to the participants.
10-1	2011-2018	Written	_
10-2	2019-2027	informed	_
10-3	2028-2035	consent	_
10-4	2036-2039	was	_
10-5	2040-2048	obtained	_
10-6	2049-2054	after	_
10-7	2055-2058	the	_
10-8	2059-2071	experimental	_
10-9	2072-2081	procedure	_
10-10	2082-2085	was	_
10-11	2086-2095	explained	_
10-12	2096-2098	to	_
10-13	2099-2102	the	_
10-14	2103-2115	participants	_
10-15	2116-2117	.	_

Text=A total of n = 23 CUD and n = 23 HC participants were recruited from the New York metropolitan area and were matched for age (range: 34–50), gender (4 females in each group), body mass index, education years, and intelligence quotient (IQ) (see Table 1 for demographic details of each group).
11-1	2118-2119	A	_
11-2	2120-2125	total	_
11-3	2126-2128	of	_
11-4	2129-2130	n	_
11-5	2131-2132	=	_
11-6	2133-2135	23	_
11-7	2136-2139	CUD	_
11-8	2140-2143	and	_
11-9	2144-2145	n	_
11-10	2146-2147	=	_
11-11	2148-2150	23	_
11-12	2151-2153	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-13	2154-2166	participants	_
11-14	2167-2171	were	_
11-15	2172-2181	recruited	_
11-16	2182-2186	from	_
11-17	2187-2190	the	_
11-18	2191-2194	New	_
11-19	2195-2199	York	_
11-20	2200-2212	metropolitan	_
11-21	2213-2217	area	_
11-22	2218-2221	and	_
11-23	2222-2226	were	_
11-24	2227-2234	matched	_
11-25	2235-2238	for	_
11-26	2239-2242	age	_
11-27	2243-2244	(	_
11-28	2245-2250	range	_
11-29	2251-2252	:	_
11-30	2253-2258	34–50	_
11-31	2259-2260	)	_
11-32	2261-2262	,	_
11-33	2263-2269	gender	_
11-34	2270-2271	(	_
11-35	2272-2273	4	_
11-36	2274-2281	females	_
11-37	2282-2284	in	_
11-38	2285-2289	each	_
11-39	2290-2295	group	_
11-40	2296-2297	)	_
11-41	2298-2299	,	_
11-42	2300-2304	body	_
11-43	2305-2309	mass	_
11-44	2310-2315	index	_
11-45	2316-2317	,	_
11-46	2318-2327	education	_
11-47	2328-2333	years	_
11-48	2334-2335	,	_
11-49	2336-2339	and	_
11-50	2340-2352	intelligence	_
11-51	2353-2361	quotient	_
11-52	2362-2363	(	_
11-53	2364-2366	IQ	_
11-54	2367-2368	)	_
11-55	2369-2370	(	_
11-56	2371-2374	see	_
11-57	2375-2380	Table	_
11-58	2381-2382	1	_
11-59	2383-2386	for	_
11-60	2387-2398	demographic	_
11-61	2399-2406	details	_
11-62	2407-2409	of	_
11-63	2410-2414	each	_
11-64	2415-2420	group	_
11-65	2421-2422	)	_
11-66	2423-2424	.	_

Text=Participants completed the Full-Scale IQ from the Wechsler Adult Intelligence Scale, and Barona estimates were computed by incorporating race, region of the country in which the person is living, and whether they live in an urban or rural environment.
12-1	2425-2437	Participants	_
12-2	2438-2447	completed	_
12-3	2448-2451	the	_
12-4	2452-2462	Full-Scale	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
12-5	2463-2465	IQ	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
12-6	2466-2470	from	_
12-7	2471-2474	the	_
12-8	2475-2483	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
12-9	2484-2489	Adult	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
12-10	2490-2502	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
12-11	2503-2508	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
12-12	2509-2510	,	_
12-13	2511-2514	and	_
12-14	2515-2521	Barona	_
12-15	2522-2531	estimates	_
12-16	2532-2536	were	_
12-17	2537-2545	computed	_
12-18	2546-2548	by	_
12-19	2549-2562	incorporating	_
12-20	2563-2567	race	_
12-21	2568-2569	,	_
12-22	2570-2576	region	_
12-23	2577-2579	of	_
12-24	2580-2583	the	_
12-25	2584-2591	country	_
12-26	2592-2594	in	_
12-27	2595-2600	which	_
12-28	2601-2604	the	_
12-29	2605-2611	person	_
12-30	2612-2614	is	_
12-31	2615-2621	living	_
12-32	2622-2623	,	_
12-33	2624-2627	and	_
12-34	2628-2635	whether	_
12-35	2636-2640	they	_
12-36	2641-2645	live	_
12-37	2646-2648	in	_
12-38	2649-2651	an	_
12-39	2652-2657	urban	_
12-40	2658-2660	or	_
12-41	2661-2666	rural	_
12-42	2667-2678	environment	_
12-43	2679-2680	.	_

Text=There were also no differences in ethnicity between the CUD (African American: n = 18, Caucasian: n = 4, mixed ancestry: n = 1) and HC group (African American: n = 18, Caucasian: n = 3, mixed ancestry: n = 2; χ246,2 = 0.5, p = 0.8), which has been shown to be associated with D2R.
13-1	2681-2686	There	_
13-2	2687-2691	were	_
13-3	2692-2696	also	_
13-4	2697-2699	no	_
13-5	2700-2711	differences	_
13-6	2712-2714	in	_
13-7	2715-2724	ethnicity	_
13-8	2725-2732	between	_
13-9	2733-2736	the	_
13-10	2737-2740	CUD	_
13-11	2741-2742	(	_
13-12	2743-2750	African	_
13-13	2751-2759	American	_
13-14	2760-2761	:	_
13-15	2762-2763	n	_
13-16	2764-2765	=	_
13-17	2766-2768	18	_
13-18	2769-2770	,	_
13-19	2771-2780	Caucasian	_
13-20	2781-2782	:	_
13-21	2783-2784	n	_
13-22	2785-2786	=	_
13-23	2787-2788	4	_
13-24	2789-2790	,	_
13-25	2791-2796	mixed	_
13-26	2797-2805	ancestry	_
13-27	2806-2807	:	_
13-28	2808-2809	n	_
13-29	2810-2811	=	_
13-30	2812-2813	1	_
13-31	2814-2815	)	_
13-32	2816-2819	and	_
13-33	2820-2822	HC	_
13-34	2823-2828	group	_
13-35	2829-2830	(	_
13-36	2831-2838	African	_
13-37	2839-2847	American	_
13-38	2848-2849	:	_
13-39	2850-2851	n	_
13-40	2852-2853	=	_
13-41	2854-2856	18	_
13-42	2857-2858	,	_
13-43	2859-2868	Caucasian	_
13-44	2869-2870	:	_
13-45	2871-2872	n	_
13-46	2873-2874	=	_
13-47	2875-2876	3	_
13-48	2877-2878	,	_
13-49	2879-2884	mixed	_
13-50	2885-2893	ancestry	_
13-51	2894-2895	:	_
13-52	2896-2897	n	_
13-53	2898-2899	=	_
13-54	2900-2901	2	_
13-55	2902-2903	;	_
13-56	2904-2910	χ246,2	_
13-57	2911-2912	=	_
13-58	2913-2916	0.5	_
13-59	2917-2918	,	_
13-60	2919-2920	p	_
13-61	2921-2922	=	_
13-62	2923-2926	0.8	_
13-63	2927-2928	)	_
13-64	2929-2930	,	_
13-65	2931-2936	which	_
13-66	2937-2940	has	_
13-67	2941-2945	been	_
13-68	2946-2951	shown	_
13-69	2952-2954	to	_
13-70	2955-2957	be	_
13-71	2958-2968	associated	_
13-72	2969-2973	with	_
13-73	2974-2977	D2R	_
13-74	2978-2979	.	_

Text=There were, however, more smokers in the CUD (current smokers: n = 20, ex-smokers: n = 1, never-smokers: n = 2) compared to the HC group (current smokers: n = 3, ex-smokers: n = 1, never-smokers: n = 19; χ246,2 = 26.3, p <0.001).
14-1	2980-2985	There	_
14-2	2986-2990	were	_
14-3	2991-2992	,	_
14-4	2993-3000	however	_
14-5	3001-3002	,	_
14-6	3003-3007	more	_
14-7	3008-3015	smokers	_
14-8	3016-3018	in	_
14-9	3019-3022	the	_
14-10	3023-3026	CUD	_
14-11	3027-3028	(	_
14-12	3029-3036	current	_
14-13	3037-3044	smokers	_
14-14	3045-3046	:	_
14-15	3047-3048	n	_
14-16	3049-3050	=	_
14-17	3051-3053	20	_
14-18	3054-3055	,	_
14-19	3056-3066	ex-smokers	_
14-20	3067-3068	:	_
14-21	3069-3070	n	_
14-22	3071-3072	=	_
14-23	3073-3074	1	_
14-24	3075-3076	,	_
14-25	3077-3090	never-smokers	_
14-26	3091-3092	:	_
14-27	3093-3094	n	_
14-28	3095-3096	=	_
14-29	3097-3098	2	_
14-30	3099-3100	)	_
14-31	3101-3109	compared	_
14-32	3110-3112	to	_
14-33	3113-3116	the	_
14-34	3117-3119	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
14-35	3120-3125	group	_
14-36	3126-3127	(	_
14-37	3128-3135	current	_
14-38	3136-3143	smokers	_
14-39	3144-3145	:	_
14-40	3146-3147	n	_
14-41	3148-3149	=	_
14-42	3150-3151	3	_
14-43	3152-3153	,	_
14-44	3154-3164	ex-smokers	_
14-45	3165-3166	:	_
14-46	3167-3168	n	_
14-47	3169-3170	=	_
14-48	3171-3172	1	_
14-49	3173-3174	,	_
14-50	3175-3188	never-smokers	_
14-51	3189-3190	:	_
14-52	3191-3192	n	_
14-53	3193-3194	=	_
14-54	3195-3197	19	_
14-55	3198-3199	;	_
14-56	3200-3206	χ246,2	_
14-57	3207-3208	=	_
14-58	3209-3213	26.3	_
14-59	3214-3215	,	_
14-60	3216-3217	p	_
14-61	3218-3219	<	_
14-62	3220-3225	0.001	_
14-63	3226-3227	)	_
14-64	3228-3229	.	_

Text=Result on the effects of MP when it was not expected were previously published as part of a larger study that compared the effects of MP between CUD and HC.
15-1	3230-3236	Result	_
15-2	3237-3239	on	_
15-3	3240-3243	the	_
15-4	3244-3251	effects	_
15-5	3252-3254	of	_
15-6	3255-3257	MP	_
15-7	3258-3262	when	_
15-8	3263-3265	it	_
15-9	3266-3269	was	_
15-10	3270-3273	not	_
15-11	3274-3282	expected	_
15-12	3283-3287	were	_
15-13	3288-3298	previously	_
15-14	3299-3308	published	_
15-15	3309-3311	as	_
15-16	3312-3316	part	_
15-17	3317-3319	of	_
15-18	3320-3321	a	_
15-19	3322-3328	larger	_
15-20	3329-3334	study	_
15-21	3335-3339	that	_
15-22	3340-3348	compared	_
15-23	3349-3352	the	_
15-24	3353-3360	effects	_
15-25	3361-3363	of	_
15-26	3364-3366	MP	_
15-27	3367-3374	between	_
15-28	3375-3378	CUD	_
15-29	3379-3382	and	_
15-30	3383-3385	HC	_
15-31	3386-3387	.	_

Text=However, this study is the first in reporting the effect of Expectation on D2R availability in CUD after PL and after MP and in comparing the Expectation responses to PL and to MP between controls and CUD.
16-1	3388-3395	However	_
16-2	3396-3397	,	_
16-3	3398-3402	this	_
16-4	3403-3408	study	_
16-5	3409-3411	is	_
16-6	3412-3415	the	_
16-7	3416-3421	first	_
16-8	3422-3424	in	_
16-9	3425-3434	reporting	_
16-10	3435-3438	the	_
16-11	3439-3445	effect	_
16-12	3446-3448	of	_
16-13	3449-3460	Expectation	_
16-14	3461-3463	on	_
16-15	3464-3467	D2R	_
16-16	3468-3480	availability	_
16-17	3481-3483	in	_
16-18	3484-3487	CUD	_
16-19	3488-3493	after	_
16-20	3494-3496	PL	_
16-21	3497-3500	and	_
16-22	3501-3506	after	_
16-23	3507-3509	MP	_
16-24	3510-3513	and	_
16-25	3514-3516	in	_
16-26	3517-3526	comparing	_
16-27	3527-3530	the	_
16-28	3531-3542	Expectation	_
16-29	3543-3552	responses	_
16-30	3553-3555	to	_
16-31	3556-3558	PL	_
16-32	3559-3562	and	_
16-33	3563-3565	to	_
16-34	3566-3568	MP	_
16-35	3569-3576	between	_
16-36	3577-3585	controls	_
16-37	3586-3589	and	_
16-38	3590-3593	CUD	_
16-39	3594-3595	.	_

Text=CUD subjects were included if they met Diagnostic and Statistical Manual of Mental Disorders IV diagnosis for current cocaine dependence with at least a 2-year history of cocaine abuse (at least 3 g/week), use cocaine predominantly by smoked or intravenous (iv) route, and presently intended to continue using cocaine.
17-1	3596-3599	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse
17-2	3600-3608	subjects	_
17-3	3609-3613	were	_
17-4	3614-3622	included	_
17-5	3623-3625	if	_
17-6	3626-3630	they	_
17-7	3631-3634	met	_
17-8	3635-3645	Diagnostic	_
17-9	3646-3649	and	_
17-10	3650-3661	Statistical	_
17-11	3662-3668	Manual	_
17-12	3669-3671	of	_
17-13	3672-3678	Mental	_
17-14	3679-3688	Disorders	_
17-15	3689-3691	IV	_
17-16	3692-3701	diagnosis	_
17-17	3702-3705	for	_
17-18	3706-3713	current	_
17-19	3714-3721	cocaine	_
17-20	3722-3732	dependence	_
17-21	3733-3737	with	_
17-22	3738-3740	at	_
17-23	3741-3746	least	_
17-24	3747-3748	a	_
17-25	3749-3755	2-year	_
17-26	3756-3763	history	_
17-27	3764-3766	of	_
17-28	3767-3774	cocaine	_
17-29	3775-3780	abuse	_
17-30	3781-3782	(	_
17-31	3783-3785	at	_
17-32	3786-3791	least	_
17-33	3792-3793	3	_
17-34	3794-3800	g/week	_
17-35	3801-3802	)	_
17-36	3803-3804	,	_
17-37	3805-3808	use	_
17-38	3809-3816	cocaine	_
17-39	3817-3830	predominantly	_
17-40	3831-3833	by	_
17-41	3834-3840	smoked	_
17-42	3841-3843	or	_
17-43	3844-3855	intravenous	_
17-44	3856-3857	(	_
17-45	3858-3860	iv	_
17-46	3861-3862	)	_
17-47	3863-3868	route	_
17-48	3869-3870	,	_
17-49	3871-3874	and	_
17-50	3875-3884	presently	_
17-51	3885-3893	intended	_
17-52	3894-3896	to	_
17-53	3897-3905	continue	_
17-54	3906-3911	using	_
17-55	3912-3919	cocaine	_
17-56	3920-3921	.	_

Text=The inclusion criteria for the HC subjects were a prior experience of using stimulant (i.e., cocaine, methamphetamine, MP) at least once but no presence or history of other substance use disorders than nicotine.
18-1	3922-3925	The	_
18-2	3926-3935	inclusion	_
18-3	3936-3944	criteria	_
18-4	3945-3948	for	_
18-5	3949-3952	the	_
18-6	3953-3955	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-7	3956-3964	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
18-8	3965-3969	were	_
18-9	3970-3971	a	_
18-10	3972-3977	prior	_
18-11	3978-3988	experience	_
18-12	3989-3991	of	_
18-13	3992-3997	using	_
18-14	3998-4007	stimulant	_
18-15	4008-4009	(	_
18-16	4010-4014	i.e.	_
18-17	4015-4016	,	_
18-18	4017-4024	cocaine	_
18-19	4025-4026	,	_
18-20	4027-4042	methamphetamine	_
18-21	4043-4044	,	_
18-22	4045-4047	MP	_
18-23	4048-4049	)	_
18-24	4050-4052	at	_
18-25	4053-4058	least	_
18-26	4059-4063	once	_
18-27	4064-4067	but	_
18-28	4068-4070	no	_
18-29	4071-4079	presence	_
18-30	4080-4082	or	_
18-31	4083-4090	history	_
18-32	4091-4093	of	_
18-33	4094-4099	other	_
18-34	4100-4109	substance	_
18-35	4110-4113	use	_
18-36	4114-4123	disorders	_
18-37	4124-4128	than	_
18-38	4129-4137	nicotine	_
18-39	4138-4139	.	_

Text=CUD and HC were excluded if they had current or a history of neurological disease of central origin or psychiatric disease including seizures, high levels of anxiety, panic attacks, psychosis; current medical illness that may affect brain function; current or history of cardiovascular disease; head trauma with loss of consciousness> 30 min; urine positive for psychoactive drugs; and history of vascular headaches.
19-1	4140-4143	CUD	_
19-2	4144-4147	and	_
19-3	4148-4150	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-4	4151-4155	were	_
19-5	4156-4164	excluded	_
19-6	4165-4167	if	_
19-7	4168-4172	they	_
19-8	4173-4176	had	_
19-9	4177-4184	current	_
19-10	4185-4187	or	_
19-11	4188-4189	a	_
19-12	4190-4197	history	_
19-13	4198-4200	of	_
19-14	4201-4213	neurological	_
19-15	4214-4221	disease	_
19-16	4222-4224	of	_
19-17	4225-4232	central	_
19-18	4233-4239	origin	_
19-19	4240-4242	or	_
19-20	4243-4254	psychiatric	_
19-21	4255-4262	disease	_
19-22	4263-4272	including	_
19-23	4273-4281	seizures	_
19-24	4282-4283	,	_
19-25	4284-4288	high	_
19-26	4289-4295	levels	_
19-27	4296-4298	of	_
19-28	4299-4306	anxiety	_
19-29	4307-4308	,	_
19-30	4309-4314	panic	_
19-31	4315-4322	attacks	_
19-32	4323-4324	,	_
19-33	4325-4334	psychosis	_
19-34	4335-4336	;	_
19-35	4337-4344	current	_
19-36	4345-4352	medical	_
19-37	4353-4360	illness	_
19-38	4361-4365	that	_
19-39	4366-4369	may	_
19-40	4370-4376	affect	_
19-41	4377-4382	brain	_
19-42	4383-4391	function	_
19-43	4392-4393	;	_
19-44	4394-4401	current	_
19-45	4402-4404	or	_
19-46	4405-4412	history	_
19-47	4413-4415	of	_
19-48	4416-4430	cardiovascular	_
19-49	4431-4438	disease	_
19-50	4439-4440	;	_
19-51	4441-4445	head	_
19-52	4446-4452	trauma	_
19-53	4453-4457	with	_
19-54	4458-4462	loss	_
19-55	4463-4465	of	_
19-56	4466-4479	consciousness	_
19-57	4480-4481	>	_
19-58	4482-4484	30	_
19-59	4485-4488	min	_
19-60	4489-4490	;	_
19-61	4491-4496	urine	_
19-62	4497-4505	positive	_
19-63	4506-4509	for	_
19-64	4510-4522	psychoactive	_
19-65	4523-4528	drugs	_
19-66	4529-4530	;	_
19-67	4531-4534	and	_
19-68	4535-4542	history	_
19-69	4543-4545	of	_
19-70	4546-4554	vascular	_
19-71	4555-4564	headaches	_
19-72	4565-4566	.	_

Text=Study design Participants were scanned with 4 PET scans and [11C] raclopride after MP (0.5 mg/kg iv) or PL.
20-1	4567-4572	Study	_
20-2	4573-4579	design	_
20-3	4580-4592	Participants	_
20-4	4593-4597	were	_
20-5	4598-4605	scanned	_
20-6	4606-4610	with	_
20-7	4611-4612	4	_
20-8	4613-4616	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
20-9	4617-4622	scans	_
20-10	4623-4626	and	_
20-11	4627-4628	[	_
20-12	4629-4632	11C	_
20-13	4633-4634	]	_
20-14	4635-4645	raclopride	_
20-15	4646-4651	after	_
20-16	4652-4654	MP	_
20-17	4655-4656	(	_
20-18	4657-4660	0.5	_
20-19	4661-4666	mg/kg	_
20-20	4667-4669	iv	_
20-21	4670-4671	)	_
20-22	4672-4674	or	_
20-23	4675-4677	PL	_
20-24	4678-4679	.	_

Text=Brain DA D2R availability was measured in 2 days under 4 conditions on two different days: (1) PL/PL: expecting PL and receiving PL, (2) PL/MP: expecting PL and receiving MP, (3) MP/PL: expecting MP and receiving PL, (4) MP/MP: expecting MP and receiving MP.
21-1	4680-4685	Brain	_
21-2	4686-4688	DA	_
21-3	4689-4692	D2R	_
21-4	4693-4705	availability	_
21-5	4706-4709	was	_
21-6	4710-4718	measured	_
21-7	4719-4721	in	_
21-8	4722-4723	2	_
21-9	4724-4728	days	_
21-10	4729-4734	under	_
21-11	4735-4736	4	_
21-12	4737-4747	conditions	_
21-13	4748-4750	on	_
21-14	4751-4754	two	_
21-15	4755-4764	different	_
21-16	4765-4769	days	_
21-17	4770-4771	:	_
21-18	4772-4773	(	_
21-19	4774-4775	1	_
21-20	4776-4777	)	_
21-21	4778-4783	PL/PL	_
21-22	4784-4785	:	_
21-23	4786-4795	expecting	_
21-24	4796-4798	PL	_
21-25	4799-4802	and	_
21-26	4803-4812	receiving	_
21-27	4813-4815	PL	_
21-28	4816-4817	,	_
21-29	4818-4819	(	_
21-30	4820-4821	2	_
21-31	4822-4823	)	_
21-32	4824-4829	PL/MP	_
21-33	4830-4831	:	_
21-34	4832-4841	expecting	_
21-35	4842-4844	PL	_
21-36	4845-4848	and	_
21-37	4849-4858	receiving	_
21-38	4859-4861	MP	_
21-39	4862-4863	,	_
21-40	4864-4865	(	_
21-41	4866-4867	3	_
21-42	4868-4869	)	_
21-43	4870-4875	MP/PL	_
21-44	4876-4877	:	_
21-45	4878-4887	expecting	_
21-46	4888-4890	MP	_
21-47	4891-4894	and	_
21-48	4895-4904	receiving	_
21-49	4905-4907	PL	_
21-50	4908-4909	,	_
21-51	4910-4911	(	_
21-52	4912-4913	4	_
21-53	4914-4915	)	_
21-54	4916-4921	MP/MP	_
21-55	4922-4923	:	_
21-56	4924-4933	expecting	_
21-57	4934-4936	MP	_
21-58	4937-4940	and	_
21-59	4941-4950	receiving	_
21-60	4951-4953	MP	_
21-61	4954-4955	.	_

Text=The order of sessions was pseudo-randomized over 2 days and equally distributed over diagnostic groups.
22-1	4956-4959	The	_
22-2	4960-4965	order	_
22-3	4966-4968	of	_
22-4	4969-4977	sessions	_
22-5	4978-4981	was	_
22-6	4982-4999	pseudo-randomized	_
22-7	5000-5004	over	_
22-8	5005-5006	2	_
22-9	5007-5011	days	_
22-10	5012-5015	and	_
22-11	5016-5023	equally	_
22-12	5024-5035	distributed	_
22-13	5036-5040	over	_
22-14	5041-5051	diagnostic	_
22-15	5052-5058	groups	_
22-16	5059-5060	.	_

Text=For practical reasons, receiving MP was always provided after receiving PL (always the second scan on a given day) to avoid the pharmacological effects of MP that would otherwise affect the following scan, providing the following combinations: day A: PL/PL following PL/MP and day B: MP/PL following MP/MP; or day A: PL/PL following MP/MP and day B: MP/PL following PL/MP.
23-1	5061-5064	For	_
23-2	5065-5074	practical	_
23-3	5075-5082	reasons	_
23-4	5083-5084	,	_
23-5	5085-5094	receiving	_
23-6	5095-5097	MP	_
23-7	5098-5101	was	_
23-8	5102-5108	always	_
23-9	5109-5117	provided	_
23-10	5118-5123	after	_
23-11	5124-5133	receiving	_
23-12	5134-5136	PL	_
23-13	5137-5138	(	_
23-14	5139-5145	always	_
23-15	5146-5149	the	_
23-16	5150-5156	second	_
23-17	5157-5161	scan	_
23-18	5162-5164	on	_
23-19	5165-5166	a	_
23-20	5167-5172	given	_
23-21	5173-5176	day	_
23-22	5177-5178	)	_
23-23	5179-5181	to	_
23-24	5182-5187	avoid	_
23-25	5188-5191	the	_
23-26	5192-5207	pharmacological	_
23-27	5208-5215	effects	_
23-28	5216-5218	of	_
23-29	5219-5221	MP	_
23-30	5222-5226	that	_
23-31	5227-5232	would	_
23-32	5233-5242	otherwise	_
23-33	5243-5249	affect	_
23-34	5250-5253	the	_
23-35	5254-5263	following	_
23-36	5264-5268	scan	_
23-37	5269-5270	,	_
23-38	5271-5280	providing	_
23-39	5281-5284	the	_
23-40	5285-5294	following	_
23-41	5295-5307	combinations	_
23-42	5308-5309	:	_
23-43	5310-5313	day	_
23-44	5314-5315	A	_
23-45	5316-5317	:	_
23-46	5318-5323	PL/PL	_
23-47	5324-5333	following	_
23-48	5334-5339	PL/MP	_
23-49	5340-5343	and	_
23-50	5344-5347	day	_
23-51	5348-5349	B	_
23-52	5350-5351	:	_
23-53	5352-5357	MP/PL	_
23-54	5358-5367	following	_
23-55	5368-5373	MP/MP	_
23-56	5374-5375	;	_
23-57	5376-5378	or	_
23-58	5379-5382	day	_
23-59	5383-5384	A	_
23-60	5385-5386	:	_
23-61	5387-5392	PL/PL	_
23-62	5393-5402	following	_
23-63	5403-5408	MP/MP	_
23-64	5409-5412	and	_
23-65	5413-5416	day	_
23-66	5417-5418	B	_
23-67	5419-5420	:	_
23-68	5421-5426	MP/PL	_
23-69	5427-5436	following	_
23-70	5437-5442	PL/MP	_
23-71	5443-5444	.	_

Text=MP (0.5 mg/kg) or PL (saline 3.0 ml) was administrated iv for 30 s. Drug expectation Thirty minutes before the injections, participants were told by the experimenter which injection they would receive (PL or MP).
24-1	5445-5447	MP	_
24-2	5448-5449	(	_
24-3	5450-5453	0.5	_
24-4	5454-5459	mg/kg	_
24-5	5460-5461	)	_
24-6	5462-5464	or	_
24-7	5465-5467	PL	_
24-8	5468-5469	(	_
24-9	5470-5476	saline	_
24-10	5477-5480	3.0	_
24-11	5481-5483	ml	_
24-12	5484-5485	)	_
24-13	5486-5489	was	_
24-14	5490-5503	administrated	_
24-15	5504-5506	iv	_
24-16	5507-5510	for	_
24-17	5511-5513	30	_
24-18	5514-5516	s.	_
24-19	5517-5521	Drug	_
24-20	5522-5533	expectation	_
24-21	5534-5540	Thirty	_
24-22	5541-5548	minutes	_
24-23	5549-5555	before	_
24-24	5556-5559	the	_
24-25	5560-5570	injections	_
24-26	5571-5572	,	_
24-27	5573-5585	participants	_
24-28	5586-5590	were	_
24-29	5591-5595	told	_
24-30	5596-5598	by	_
24-31	5599-5602	the	_
24-32	5603-5615	experimenter	_
24-33	5616-5621	which	_
24-34	5622-5631	injection	_
24-35	5632-5636	they	_
24-36	5637-5642	would	_
24-37	5643-5650	receive	_
24-38	5651-5652	(	_
24-39	5653-5655	PL	_
24-40	5656-5658	or	_
24-41	5659-5661	MP	_
24-42	5662-5663	)	_
24-43	5664-5665	.	_

Text=Participants were also told that there was a chance that they would be deceived.
25-1	5666-5678	Participants	_
25-2	5679-5683	were	_
25-3	5684-5688	also	_
25-4	5689-5693	told	_
25-5	5694-5698	that	_
25-6	5699-5704	there	_
25-7	5705-5708	was	_
25-8	5709-5710	a	_
25-9	5711-5717	chance	_
25-10	5718-5722	that	_
25-11	5723-5727	they	_
25-12	5728-5733	would	_
25-13	5734-5736	be	_
25-14	5737-5745	deceived	_
25-15	5746-5747	.	_

Text=Participants were not debriefed after their scans to minimize learning effects on the effects of MP or PL.
26-1	5748-5760	Participants	_
26-2	5761-5765	were	_
26-3	5766-5769	not	_
26-4	5770-5779	debriefed	_
26-5	5780-5785	after	_
26-6	5786-5791	their	_
26-7	5792-5797	scans	_
26-8	5798-5800	to	_
26-9	5801-5809	minimize	_
26-10	5810-5818	learning	_
26-11	5819-5826	effects	_
26-12	5827-5829	on	_
26-13	5830-5833	the	_
26-14	5834-5841	effects	_
26-15	5842-5844	of	_
26-16	5845-5847	MP	_
26-17	5848-5850	or	_
26-18	5851-5853	PL	_
26-19	5854-5855	.	_

Text=Plasma MP concentrations, cardiovascular, and self-report ratings Blood samples were obtained to measure plasma MP concentration prior to and at 15, 30, 45, and 60 min after MP.
27-1	5856-5862	Plasma	_
27-2	5863-5865	MP	_
27-3	5866-5880	concentrations	_
27-4	5881-5882	,	_
27-5	5883-5897	cardiovascular	_
27-6	5898-5899	,	_
27-7	5900-5903	and	_
27-8	5904-5915	self-report	_
27-9	5916-5923	ratings	_
27-10	5924-5929	Blood	_
27-11	5930-5937	samples	_
27-12	5938-5942	were	_
27-13	5943-5951	obtained	_
27-14	5952-5954	to	_
27-15	5955-5962	measure	_
27-16	5963-5969	plasma	_
27-17	5970-5972	MP	_
27-18	5973-5986	concentration	_
27-19	5987-5992	prior	_
27-20	5993-5995	to	_
27-21	5996-5999	and	_
27-22	6000-6002	at	_
27-23	6003-6005	15	_
27-24	6006-6007	,	_
27-25	6008-6010	30	_
27-26	6011-6012	,	_
27-27	6013-6015	45	_
27-28	6016-6017	,	_
27-29	6018-6021	and	_
27-30	6022-6024	60	_
27-31	6025-6028	min	_
27-32	6029-6034	after	_
27-33	6035-6037	MP	_
27-34	6038-6039	.	_

Text=The plasma concentration of MP was analyzed at Dr. Thomas Cooper ’ s laboratory (Nathan Kline Institute, New York).
28-1	6040-6043	The	_
28-2	6044-6050	plasma	_
28-3	6051-6064	concentration	_
28-4	6065-6067	of	_
28-5	6068-6070	MP	_
28-6	6071-6074	was	_
28-7	6075-6083	analyzed	_
28-8	6084-6086	at	_
28-9	6087-6090	Dr.	_
28-10	6091-6097	Thomas	_
28-11	6098-6104	Cooper	_
28-12	6105-6106	’	_
28-13	6107-6108	s	_
28-14	6109-6119	laboratory	_
28-15	6120-6121	(	_
28-16	6122-6128	Nathan	_
28-17	6129-6134	Kline	_
28-18	6135-6144	Institute	_
28-19	6145-6146	,	_
28-20	6147-6150	New	_
28-21	6151-6155	York	_
28-22	6156-6157	)	_
28-23	6158-6159	.	_

Text=In addition, cardiovascular responses (i.e., heart rate, blood pressure, and EKG lead II) and self-report ratings (i.e., high, rush, anxious) to MP and PL were recorded prior to their injection and then every minute for the first 20 min after injection, then every 5 min at the end of the MP and PL PET scans.
29-1	6160-6162	In	_
29-2	6163-6171	addition	_
29-3	6172-6173	,	_
29-4	6174-6188	cardiovascular	_
29-5	6189-6198	responses	_
29-6	6199-6200	(	_
29-7	6201-6205	i.e.	_
29-8	6206-6207	,	_
29-9	6208-6213	heart	_
29-10	6214-6218	rate	_
29-11	6219-6220	,	_
29-12	6221-6226	blood	_
29-13	6227-6235	pressure	_
29-14	6236-6237	,	_
29-15	6238-6241	and	_
29-16	6242-6245	EKG	_
29-17	6246-6250	lead	_
29-18	6251-6253	II	_
29-19	6254-6255	)	_
29-20	6256-6259	and	_
29-21	6260-6271	self-report	_
29-22	6272-6279	ratings	_
29-23	6280-6281	(	_
29-24	6282-6286	i.e.	_
29-25	6287-6288	,	_
29-26	6289-6293	high	_
29-27	6294-6295	,	_
29-28	6296-6300	rush	_
29-29	6301-6302	,	_
29-30	6303-6310	anxious	_
29-31	6311-6312	)	_
29-32	6313-6315	to	_
29-33	6316-6318	MP	_
29-34	6319-6322	and	_
29-35	6323-6325	PL	_
29-36	6326-6330	were	_
29-37	6331-6339	recorded	_
29-38	6340-6345	prior	_
29-39	6346-6348	to	_
29-40	6349-6354	their	_
29-41	6355-6364	injection	_
29-42	6365-6368	and	_
29-43	6369-6373	then	_
29-44	6374-6379	every	_
29-45	6380-6386	minute	_
29-46	6387-6390	for	_
29-47	6391-6394	the	_
29-48	6395-6400	first	_
29-49	6401-6403	20	_
29-50	6404-6407	min	_
29-51	6408-6413	after	_
29-52	6414-6423	injection	_
29-53	6424-6425	,	_
29-54	6426-6430	then	_
29-55	6431-6436	every	_
29-56	6437-6438	5	_
29-57	6439-6442	min	_
29-58	6443-6445	at	_
29-59	6446-6449	the	_
29-60	6450-6453	end	_
29-61	6454-6456	of	_
29-62	6457-6460	the	_
29-63	6461-6463	MP	_
29-64	6464-6467	and	_
29-65	6468-6470	PL	_
29-66	6471-6474	PET	_
29-67	6475-6480	scans	_
29-68	6481-6482	.	_

Text=Effects of MP on cardiovascular responses and self-report ratings were tested by comparing the average scores obtained between 0 and 60 min after iv PL and MP administration using a mixed analysis of variance (ANOVA) with Group × Challenge × Expectation in SPSS 22 (IBM, Armonk, NY).
30-1	6483-6490	Effects	_
30-2	6491-6493	of	_
30-3	6494-6496	MP	_
30-4	6497-6499	on	_
30-5	6500-6514	cardiovascular	_
30-6	6515-6524	responses	_
30-7	6525-6528	and	_
30-8	6529-6540	self-report	_
30-9	6541-6548	ratings	_
30-10	6549-6553	were	_
30-11	6554-6560	tested	_
30-12	6561-6563	by	_
30-13	6564-6573	comparing	_
30-14	6574-6577	the	_
30-15	6578-6585	average	_
30-16	6586-6592	scores	_
30-17	6593-6601	obtained	_
30-18	6602-6609	between	_
30-19	6610-6611	0	_
30-20	6612-6615	and	_
30-21	6616-6618	60	_
30-22	6619-6622	min	_
30-23	6623-6628	after	_
30-24	6629-6631	iv	_
30-25	6632-6634	PL	_
30-26	6635-6638	and	_
30-27	6639-6641	MP	_
30-28	6642-6656	administration	_
30-29	6657-6662	using	_
30-30	6663-6664	a	_
30-31	6665-6670	mixed	_
30-32	6671-6679	analysis	_
30-33	6680-6682	of	_
30-34	6683-6691	variance	_
30-35	6692-6693	(	_
30-36	6694-6699	ANOVA	_
30-37	6700-6701	)	_
30-38	6702-6706	with	_
30-39	6707-6712	Group	_
30-40	6713-6714	×	_
30-41	6715-6724	Challenge	_
30-42	6725-6726	×	_
30-43	6727-6738	Expectation	_
30-44	6739-6741	in	_
30-45	6742-6746	SPSS	_
30-46	6747-6749	22	_
30-47	6750-6751	(	_
30-48	6752-6755	IBM	_
30-49	6756-6757	,	_
30-50	6758-6764	Armonk	_
30-51	6765-6766	,	_
30-52	6767-6769	NY	_
30-53	6770-6771	)	_
30-54	6772-6773	.	_

Text=Post hoc t tests were performed to determine the direction of findings.
31-1	6774-6778	Post	_
31-2	6779-6782	hoc	_
31-3	6783-6784	t	_
31-4	6785-6790	tests	_
31-5	6791-6795	were	_
31-6	6796-6805	performed	_
31-7	6806-6808	to	_
31-8	6809-6818	determine	_
31-9	6819-6822	the	_
31-10	6823-6832	direction	_
31-11	6833-6835	of	_
31-12	6836-6844	findings	_
31-13	6845-6846	.	_

Text=Cardiac data and self-reports were further correlated with MP-induced changes in striatal non-displaceable binding potential (BPND).
32-1	6847-6854	Cardiac	_
32-2	6855-6859	data	_
32-3	6860-6863	and	_
32-4	6864-6876	self-reports	_
32-5	6877-6881	were	_
32-6	6882-6889	further	_
32-7	6890-6900	correlated	_
32-8	6901-6905	with	_
32-9	6906-6916	MP-induced	_
32-10	6917-6924	changes	_
32-11	6925-6927	in	_
32-12	6928-6936	striatal	_
32-13	6937-6953	non-displaceable	_
32-14	6954-6961	binding	_
32-15	6962-6971	potential	_
32-16	6972-6973	(	_
32-17	6974-6978	BPND	_
32-18	6979-6980	)	_
32-19	6981-6982	.	_

Text=PET scanning and processing PET scans were started at 2 min after PL or MP administration for 1 h. Dynamic emission scans were done using the Siemens HR+ tomograph (4.5 × 4.5 × 4.2 mm3; three-dimensional acquisition mode) and were started after iv injection of ~7 mCi of [11C] raclopride.
33-1	6983-6986	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
33-2	6987-6995	scanning	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
33-3	6996-6999	and	_
33-4	7000-7010	processing	_
33-5	7011-7014	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
33-6	7015-7020	scans	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
33-7	7021-7025	were	_
33-8	7026-7033	started	_
33-9	7034-7036	at	_
33-10	7037-7038	2	_
33-11	7039-7042	min	_
33-12	7043-7048	after	_
33-13	7049-7051	PL	_
33-14	7052-7054	or	_
33-15	7055-7057	MP	_
33-16	7058-7072	administration	_
33-17	7073-7076	for	_
33-18	7077-7078	1	_
33-19	7079-7081	h.	_
33-20	7082-7089	Dynamic	_
33-21	7090-7098	emission	_
33-22	7099-7104	scans	_
33-23	7105-7109	were	_
33-24	7110-7114	done	_
33-25	7115-7120	using	_
33-26	7121-7124	the	_
33-27	7125-7132	Siemens	_
33-28	7133-7136	HR+	_
33-29	7137-7146	tomograph	_
33-30	7147-7148	(	_
33-31	7149-7152	4.5	_
33-32	7153-7154	×	_
33-33	7155-7158	4.5	_
33-34	7159-7160	×	_
33-35	7161-7164	4.2	_
33-36	7165-7168	mm3	_
33-37	7169-7170	;	_
33-38	7171-7188	three-dimensional	_
33-39	7189-7200	acquisition	_
33-40	7201-7205	mode	_
33-41	7206-7207	)	_
33-42	7208-7211	and	_
33-43	7212-7216	were	_
33-44	7217-7224	started	_
33-45	7225-7230	after	_
33-46	7231-7233	iv	_
33-47	7234-7243	injection	_
33-48	7244-7246	of	_
33-49	7247-7249	~7	_
33-50	7250-7253	mCi	_
33-51	7254-7256	of	_
33-52	7257-7258	[	_
33-53	7259-7262	11C	_
33-54	7263-7264	]	_
33-55	7265-7275	raclopride	_
33-56	7276-7277	.	_

Text=Twenty dynamic emission scans were obtained from the time of injection up to 60 min, which has been our standard procedure for [11C] raclopride scans, and included 15 1-min, 3 5-min and 2 15-min scans.
34-1	7278-7284	Twenty	_
34-2	7285-7292	dynamic	_
34-3	7293-7301	emission	_
34-4	7302-7307	scans	_
34-5	7308-7312	were	_
34-6	7313-7321	obtained	_
34-7	7322-7326	from	_
34-8	7327-7330	the	_
34-9	7331-7335	time	_
34-10	7336-7338	of	_
34-11	7339-7348	injection	_
34-12	7349-7351	up	_
34-13	7352-7354	to	_
34-14	7355-7357	60	_
34-15	7358-7361	min	_
34-16	7362-7363	,	_
34-17	7364-7369	which	_
34-18	7370-7373	has	_
34-19	7374-7378	been	_
34-20	7379-7382	our	_
34-21	7383-7391	standard	_
34-22	7392-7401	procedure	_
34-23	7402-7405	for	_
34-24	7406-7407	[	_
34-25	7408-7411	11C	_
34-26	7412-7413	]	_
34-27	7414-7424	raclopride	_
34-28	7425-7430	scans	_
34-29	7431-7432	,	_
34-30	7433-7436	and	_
34-31	7437-7445	included	_
34-32	7446-7448	15	_
34-33	7449-7454	1-min	_
34-34	7455-7456	,	_
34-35	7457-7458	3	_
34-36	7459-7464	5-min	_
34-37	7465-7468	and	_
34-38	7469-7470	2	_
34-39	7471-7477	15-min	_
34-40	7478-7483	scans	_
34-41	7484-7485	.	_

Text=There were 120 min between injections, thus 60 min of break between scans.
35-1	7486-7491	There	_
35-2	7492-7496	were	_
35-3	7497-7500	120	_
35-4	7501-7504	min	_
35-5	7505-7512	between	_
35-6	7513-7523	injections	_
35-7	7524-7525	,	_
35-8	7526-7530	thus	_
35-9	7531-7533	60	_
35-10	7534-7537	min	_
35-11	7538-7540	of	_
35-12	7541-7546	break	_
35-13	7547-7554	between	_
35-14	7555-7560	scans	_
35-15	7561-7562	.	_

Text=We normalized the distribution volume (DV) in each voxel to that in the cerebellum (left and right regions of interest (ROIs)) to compute the DV ratio (DVR) images.
36-1	7563-7565	We	_
36-2	7566-7576	normalized	_
36-3	7577-7580	the	_
36-4	7581-7593	distribution	_
36-5	7594-7600	volume	_
36-6	7601-7602	(	_
36-7	7603-7605	DV	_
36-8	7606-7607	)	_
36-9	7608-7610	in	_
36-10	7611-7615	each	_
36-11	7616-7621	voxel	_
36-12	7622-7624	to	_
36-13	7625-7629	that	_
36-14	7630-7632	in	_
36-15	7633-7636	the	_
36-16	7637-7647	cerebellum	_
36-17	7648-7649	(	_
36-18	7650-7654	left	_
36-19	7655-7658	and	_
36-20	7659-7664	right	_
36-21	7665-7672	regions	_
36-22	7673-7675	of	_
36-23	7676-7684	interest	_
36-24	7685-7686	(	_
36-25	7687-7691	ROIs	_
36-26	7692-7693	)	_
36-27	7694-7695	)	_
36-28	7696-7698	to	_
36-29	7699-7706	compute	_
36-30	7707-7710	the	_
36-31	7711-7713	DV	_
36-32	7714-7719	ratio	_
36-33	7720-7721	(	_
36-34	7722-7725	DVR	_
36-35	7726-7727	)	_
36-36	7728-7734	images	_
36-37	7735-7736	.	_

Text=DVR images were spatially normalized (2-mm isotropic voxels) to the stereotactic space of the Montreal Neurological Institute (MNI) using a 12-parameter affine transformation and a DVR template and spatially smoothed (full width half maximum, FWHM = 8 mm) in SPM8 (Wellcome Trust Centre for Neuroimaging, London, UK).
37-1	7737-7740	DVR	_
37-2	7741-7747	images	_
37-3	7748-7752	were	_
37-4	7753-7762	spatially	_
37-5	7763-7773	normalized	_
37-6	7774-7775	(	_
37-7	7776-7780	2-mm	_
37-8	7781-7790	isotropic	_
37-9	7791-7797	voxels	_
37-10	7798-7799	)	_
37-11	7800-7802	to	_
37-12	7803-7806	the	_
37-13	7807-7819	stereotactic	_
37-14	7820-7825	space	_
37-15	7826-7828	of	_
37-16	7829-7832	the	_
37-17	7833-7841	Montreal	_
37-18	7842-7854	Neurological	_
37-19	7855-7864	Institute	_
37-20	7865-7866	(	_
37-21	7867-7870	MNI	_
37-22	7871-7872	)	_
37-23	7873-7878	using	_
37-24	7879-7880	a	_
37-25	7881-7893	12-parameter	_
37-26	7894-7900	affine	_
37-27	7901-7915	transformation	_
37-28	7916-7919	and	_
37-29	7920-7921	a	_
37-30	7922-7925	DVR	_
37-31	7926-7934	template	_
37-32	7935-7938	and	_
37-33	7939-7948	spatially	_
37-34	7949-7957	smoothed	_
37-35	7958-7959	(	_
37-36	7960-7964	full	_
37-37	7965-7970	width	_
37-38	7971-7975	half	_
37-39	7976-7983	maximum	_
37-40	7984-7985	,	_
37-41	7986-7990	FWHM	_
37-42	7991-7992	=	_
37-43	7993-7994	8	_
37-44	7995-7997	mm	_
37-45	7998-7999	)	_
37-46	8000-8002	in	_
37-47	8003-8007	SPM8	_
37-48	8008-8009	(	_
37-49	8010-8018	Wellcome	_
37-50	8019-8024	Trust	_
37-51	8025-8031	Centre	_
37-52	8032-8035	for	_
37-53	8036-8048	Neuroimaging	_
37-54	8049-8050	,	_
37-55	8051-8057	London	_
37-56	8058-8059	,	_
37-57	8060-8062	UK	_
37-58	8063-8064	)	_
37-59	8065-8066	.	_

Text=The DVR template was developed from DVR images of 34 healthy subjects that were acquired with [11C] raclopride using the same PET scanning sequence.
38-1	8067-8070	The	_
38-2	8071-8074	DVR	http://maven.renci.org/NeuroBridge/neurobridge#Thing
38-3	8075-8083	template	_
38-4	8084-8087	was	_
38-5	8088-8097	developed	_
38-6	8098-8102	from	_
38-7	8103-8106	DVR	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
38-8	8107-8113	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
38-9	8114-8116	of	_
38-10	8117-8119	34	_
38-11	8120-8127	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
38-12	8128-8136	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
38-13	8137-8141	that	_
38-14	8142-8146	were	_
38-15	8147-8155	acquired	_
38-16	8156-8160	with	_
38-17	8161-8162	[	_
38-18	8163-8166	11C	_
38-19	8167-8168	]	_
38-20	8169-8179	raclopride	_
38-21	8180-8185	using	_
38-22	8186-8189	the	_
38-23	8190-8194	same	_
38-24	8195-8198	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
38-25	8199-8207	scanning	_
38-26	8208-8216	sequence	_
38-27	8217-8218	.	_

Text=Specifically, all 34 images were carefully inspected to ensure whole-brain coverage and images with potential artifacts were excluded.
39-1	8219-8231	Specifically	_
39-2	8232-8233	,	_
39-3	8234-8237	all	_
39-4	8238-8240	34	_
39-5	8241-8247	images	_
39-6	8248-8252	were	_
39-7	8253-8262	carefully	_
39-8	8263-8272	inspected	_
39-9	8273-8275	to	_
39-10	8276-8282	ensure	_
39-11	8283-8294	whole-brain	_
39-12	8295-8303	coverage	_
39-13	8304-8307	and	_
39-14	8308-8314	images	_
39-15	8315-8319	with	_
39-16	8320-8329	potential	_
39-17	8330-8339	artifacts	_
39-18	8340-8344	were	_
39-19	8345-8353	excluded	_
39-20	8354-8355	.	_

Text=A 12-parameter affine transformation with 16 nonlinear iterations was used to register the 34 images to the PD.mnc MNI template provided with the SPM8 package.
40-1	8356-8357	A	_
40-2	8358-8370	12-parameter	_
40-3	8371-8377	affine	_
40-4	8378-8392	transformation	_
40-5	8393-8397	with	_
40-6	8398-8400	16	_
40-7	8401-8410	nonlinear	_
40-8	8411-8421	iterations	_
40-9	8422-8425	was	_
40-10	8426-8430	used	_
40-11	8431-8433	to	_
40-12	8434-8442	register	_
40-13	8443-8446	the	_
40-14	8447-8449	34	_
40-15	8450-8456	images	_
40-16	8457-8459	to	_
40-17	8460-8463	the	_
40-18	8464-8470	PD.mnc	_
40-19	8471-8474	MNI	_
40-20	8475-8483	template	_
40-21	8484-8492	provided	_
40-22	8493-8497	with	_
40-23	8498-8501	the	_
40-24	8502-8506	SPM8	_
40-25	8507-8514	package	_
40-26	8515-8516	.	_

Text=The images were resliced using the bounding box: x = 90:90 mm, y = 126:90 mm, and z = 72:108 mm and a voxel size of 2 × 2 × 2 mm3 using bilinear interpolation, averaged and smoothed (FWHM = 8 mm) to compute BPND in MNI space, which corresponds to D2R availability.
41-1	8517-8520	The	_
41-2	8521-8527	images	_
41-3	8528-8532	were	_
41-4	8533-8541	resliced	_
41-5	8542-8547	using	_
41-6	8548-8551	the	_
41-7	8552-8560	bounding	_
41-8	8561-8564	box	_
41-9	8565-8566	:	_
41-10	8567-8568	x	_
41-11	8569-8570	=	_
41-12	8571-8576	90:90	_
41-13	8577-8579	mm	_
41-14	8580-8581	,	_
41-15	8582-8583	y	_
41-16	8584-8585	=	_
41-17	8586-8592	126:90	_
41-18	8593-8595	mm	_
41-19	8596-8597	,	_
41-20	8598-8601	and	_
41-21	8602-8603	z	_
41-22	8604-8605	=	_
41-23	8606-8612	72:108	_
41-24	8613-8615	mm	_
41-25	8616-8619	and	_
41-26	8620-8621	a	_
41-27	8622-8627	voxel	_
41-28	8628-8632	size	_
41-29	8633-8635	of	_
41-30	8636-8637	2	_
41-31	8638-8639	×	_
41-32	8640-8641	2	_
41-33	8642-8643	×	_
41-34	8644-8645	2	_
41-35	8646-8649	mm3	_
41-36	8650-8655	using	_
41-37	8656-8664	bilinear	_
41-38	8665-8678	interpolation	_
41-39	8679-8680	,	_
41-40	8681-8689	averaged	_
41-41	8690-8693	and	_
41-42	8694-8702	smoothed	_
41-43	8703-8704	(	_
41-44	8705-8709	FWHM	_
41-45	8710-8711	=	_
41-46	8712-8713	8	_
41-47	8714-8716	mm	_
41-48	8717-8718	)	_
41-49	8719-8721	to	_
41-50	8722-8729	compute	_
41-51	8730-8734	BPND	_
41-52	8735-8737	in	_
41-53	8738-8741	MNI	_
41-54	8742-8747	space	_
41-55	8748-8749	,	_
41-56	8750-8755	which	_
41-57	8756-8767	corresponds	_
41-58	8768-8770	to	_
41-59	8771-8774	D2R	_
41-60	8775-8787	availability	_
41-61	8788-8789	.	_

Text=This left each participant with 4 BPND scans: (1) expecting PL/receiving PL, (2) expecting PL/receiving MP, (3) expecting MP/receiving PL, (4) expecting MP/receiving MP.
42-1	8790-8794	This	_
42-2	8795-8799	left	_
42-3	8800-8804	each	_
42-4	8805-8816	participant	_
42-5	8817-8821	with	_
42-6	8822-8823	4	_
42-7	8824-8828	BPND	_
42-8	8829-8834	scans	_
42-9	8835-8836	:	_
42-10	8837-8838	(	_
42-11	8839-8840	1	_
42-12	8841-8842	)	_
42-13	8843-8852	expecting	_
42-14	8853-8865	PL/receiving	_
42-15	8866-8868	PL	_
42-16	8869-8870	,	_
42-17	8871-8872	(	_
42-18	8873-8874	2	_
42-19	8875-8876	)	_
42-20	8877-8886	expecting	_
42-21	8887-8899	PL/receiving	_
42-22	8900-8902	MP	_
42-23	8903-8904	,	_
42-24	8905-8906	(	_
42-25	8907-8908	3	_
42-26	8909-8910	)	_
42-27	8911-8920	expecting	_
42-28	8921-8933	MP/receiving	_
42-29	8934-8936	PL	_
42-30	8937-8938	,	_
42-31	8939-8940	(	_
42-32	8941-8942	4	_
42-33	8943-8944	)	_
42-34	8945-8954	expecting	_
42-35	8955-8967	MP/receiving	_
42-36	8968-8970	MP	_
42-37	8971-8972	.	_

Text=Data analysis For each participant, difference scans of (receive PL–receive MP) were computed, as a measure of MP-induced DA release, both for the expecting MP and expecting PL conditions.
43-1	8973-8977	Data	_
43-2	8978-8986	analysis	_
43-3	8987-8990	For	_
43-4	8991-8995	each	_
43-5	8996-9007	participant	_
43-6	9008-9009	,	_
43-7	9010-9020	difference	_
43-8	9021-9026	scans	_
43-9	9027-9029	of	_
43-10	9030-9031	(	_
43-11	9032-9039	receive	_
43-12	9040-9050	PL–receive	_
43-13	9051-9053	MP	_
43-14	9054-9055	)	_
43-15	9056-9060	were	_
43-16	9061-9069	computed	_
43-17	9070-9071	,	_
43-18	9072-9074	as	_
43-19	9075-9076	a	_
43-20	9077-9084	measure	_
43-21	9085-9087	of	_
43-22	9088-9098	MP-induced	_
43-23	9099-9101	DA	_
43-24	9102-9109	release	_
43-25	9110-9111	,	_
43-26	9112-9116	both	_
43-27	9117-9120	for	_
43-28	9121-9124	the	_
43-29	9125-9134	expecting	_
43-30	9135-9137	MP	_
43-31	9138-9141	and	_
43-32	9142-9151	expecting	_
43-33	9152-9154	PL	_
43-34	9155-9165	conditions	_
43-35	9166-9167	.	_

Text=Voxel-wise analyses were performed in SPM8 using a mixed design ANOVA model on these DA release scans, with Group (CUD versus HC) as a between-subject factor, and Expectation (expecting PL versus expecting MP) as a within-subject factor.
44-1	9168-9178	Voxel-wise	_
44-2	9179-9187	analyses	_
44-3	9188-9192	were	_
44-4	9193-9202	performed	_
44-5	9203-9205	in	_
44-6	9206-9210	SPM8	_
44-7	9211-9216	using	_
44-8	9217-9218	a	_
44-9	9219-9224	mixed	_
44-10	9225-9231	design	_
44-11	9232-9237	ANOVA	_
44-12	9238-9243	model	_
44-13	9244-9246	on	_
44-14	9247-9252	these	_
44-15	9253-9255	DA	_
44-16	9256-9263	release	_
44-17	9264-9269	scans	_
44-18	9270-9271	,	_
44-19	9272-9276	with	_
44-20	9277-9282	Group	_
44-21	9283-9284	(	_
44-22	9285-9288	CUD	_
44-23	9289-9295	versus	_
44-24	9296-9298	HC	_
44-25	9299-9300	)	_
44-26	9301-9303	as	_
44-27	9304-9305	a	_
44-28	9306-9321	between-subject	_
44-29	9322-9328	factor	_
44-30	9329-9330	,	_
44-31	9331-9334	and	_
44-32	9335-9346	Expectation	_
44-33	9347-9348	(	_
44-34	9349-9358	expecting	_
44-35	9359-9361	PL	_
44-36	9362-9368	versus	_
44-37	9369-9378	expecting	_
44-38	9379-9381	MP	_
44-39	9382-9383	)	_
44-40	9384-9386	as	_
44-41	9387-9388	a	_
44-42	9389-9403	within-subject	_
44-43	9404-9410	factor	_
44-44	9411-9412	.	_

Text=Corrections for multiple comparisons were performed via the random field theory, an approach that is less conservative than the traditional Bonferroni method.
45-1	9413-9424	Corrections	_
45-2	9425-9428	for	_
45-3	9429-9437	multiple	_
45-4	9438-9449	comparisons	_
45-5	9450-9454	were	_
45-6	9455-9464	performed	_
45-7	9465-9468	via	_
45-8	9469-9472	the	_
45-9	9473-9479	random	_
45-10	9480-9485	field	_
45-11	9486-9492	theory	_
45-12	9493-9494	,	_
45-13	9495-9497	an	_
45-14	9498-9506	approach	_
45-15	9507-9511	that	_
45-16	9512-9514	is	_
45-17	9515-9519	less	_
45-18	9520-9532	conservative	_
45-19	9533-9537	than	_
45-20	9538-9541	the	_
45-21	9542-9553	traditional	_
45-22	9554-9564	Bonferroni	_
45-23	9565-9571	method	_
45-24	9572-9573	.	_

Text=Imaging voxels that were significantly different between conditions were identified using an uncorrected voxel threshold p ≤ 0.005 with a minimum cluster size of 100 voxels, and p <0.05 family-wise error (FWE) cluster-corrected.
46-1	9574-9581	Imaging	_
46-2	9582-9588	voxels	_
46-3	9589-9593	that	_
46-4	9594-9598	were	_
46-5	9599-9612	significantly	_
46-6	9613-9622	different	_
46-7	9623-9630	between	_
46-8	9631-9641	conditions	_
46-9	9642-9646	were	_
46-10	9647-9657	identified	_
46-11	9658-9663	using	_
46-12	9664-9666	an	_
46-13	9667-9678	uncorrected	_
46-14	9679-9684	voxel	_
46-15	9685-9694	threshold	_
46-16	9695-9696	p	_
46-17	9697-9698	≤	_
46-18	9699-9704	0.005	_
46-19	9705-9709	with	_
46-20	9710-9711	a	_
46-21	9712-9719	minimum	_
46-22	9720-9727	cluster	_
46-23	9728-9732	size	_
46-24	9733-9735	of	_
46-25	9736-9739	100	_
46-26	9740-9746	voxels	_
46-27	9747-9748	,	_
46-28	9749-9752	and	_
46-29	9753-9754	p	_
46-30	9755-9756	<	_
46-31	9757-9761	0.05	_
46-32	9762-9773	family-wise	_
46-33	9774-9779	error	_
46-34	9780-9781	(	_
46-35	9782-9785	FWE	_
46-36	9786-9787	)	_
46-37	9788-9805	cluster-corrected	_
46-38	9806-9807	.	_

Text=Moreover, for DA regions and their projections targets (caudate, putamen, NAc, midbrain), we created bilateral anatomical masks using Wake Forest University Pickatlas.
47-1	9808-9816	Moreover	_
47-2	9817-9818	,	_
47-3	9819-9822	for	_
47-4	9823-9825	DA	_
47-5	9826-9833	regions	_
47-6	9834-9837	and	_
47-7	9838-9843	their	_
47-8	9844-9855	projections	_
47-9	9856-9863	targets	_
47-10	9864-9865	(	_
47-11	9866-9873	caudate	_
47-12	9874-9875	,	_
47-13	9876-9883	putamen	_
47-14	9884-9885	,	_
47-15	9886-9889	NAc	_
47-16	9890-9891	,	_
47-17	9892-9900	midbrain	_
47-18	9901-9902	)	_
47-19	9903-9904	,	_
47-20	9905-9907	we	_
47-21	9908-9915	created	_
47-22	9916-9925	bilateral	_
47-23	9926-9936	anatomical	_
47-24	9937-9942	masks	_
47-25	9943-9948	using	_
47-26	9949-9953	Wake	_
47-27	9954-9960	Forest	_
47-28	9961-9971	University	_
47-29	9972-9981	Pickatlas	_
47-30	9982-9983	.	_

Text=For each contrast, these masks were used for small-volume correction (SVC) in SPM8 with a significance threshold of p <0.05 FWE, k> 10, as described previously.
48-1	9984-9987	For	_
48-2	9988-9992	each	_
48-3	9993-10001	contrast	_
48-4	10002-10003	,	_
48-5	10004-10009	these	_
48-6	10010-10015	masks	_
48-7	10016-10020	were	_
48-8	10021-10025	used	_
48-9	10026-10029	for	_
48-10	10030-10042	small-volume	_
48-11	10043-10053	correction	_
48-12	10054-10055	(	_
48-13	10056-10059	SVC	_
48-14	10060-10061	)	_
48-15	10062-10064	in	_
48-16	10065-10069	SPM8	_
48-17	10070-10074	with	_
48-18	10075-10076	a	_
48-19	10077-10089	significance	_
48-20	10090-10099	threshold	_
48-21	10100-10102	of	_
48-22	10103-10104	p	_
48-23	10105-10106	<	_
48-24	10107-10111	0.05	_
48-25	10112-10115	FWE	_
48-26	10116-10117	,	_
48-27	10118-10119	k	_
48-28	10120-10121	>	_
48-29	10122-10124	10	_
48-30	10125-10126	,	_
48-31	10127-10129	as	_
48-32	10130-10139	described	_
48-33	10140-10150	previously	_
48-34	10151-10152	.	_

Text=Bilateral mask sizes were the following: caudate (3571), putamen (3592), NAc (313), midbrain (2289).
49-1	10153-10162	Bilateral	_
49-2	10163-10167	mask	_
49-3	10168-10173	sizes	_
49-4	10174-10178	were	_
49-5	10179-10182	the	_
49-6	10183-10192	following	_
49-7	10193-10194	:	_
49-8	10195-10202	caudate	_
49-9	10203-10204	(	_
49-10	10205-10209	3571	_
49-11	10210-10211	)	_
49-12	10212-10213	,	_
49-13	10214-10221	putamen	_
49-14	10222-10223	(	_
49-15	10224-10228	3592	_
49-16	10229-10230	)	_
49-17	10231-10232	,	_
49-18	10233-10236	NAc	_
49-19	10237-10238	(	_
49-20	10239-10242	313	_
49-21	10243-10244	)	_
49-22	10245-10246	,	_
49-23	10247-10255	midbrain	_
49-24	10256-10257	(	_
49-25	10258-10262	2289	_
49-26	10263-10264	)	_
49-27	10265-10266	.	_

